|1.||Schlereth, Bernd: 3 articles (10/2009 - 04/2007)|
|2.||Seimetz, Diane: 2 articles (01/2011 - 10/2010)|
|3.||Brischwein, Klaus: 2 articles (10/2009 - 01/2008)|
|4.||Kufer, Peter: 2 articles (01/2008 - 04/2007)|
|5.||Lutterbuese, Ralf: 2 articles (01/2008 - 04/2007)|
|6.||Baeuerle, Patrick A: 2 articles (01/2008 - 04/2007)|
|7.||Lutterbuese, Petra: 2 articles (01/2008 - 04/2007)|
|8.||Alroy, Joseph: 2 articles (01/2005 - 01/2003)|
|9.||Shen, Jingjing: 1 article (08/2015)|
|10.||Wagner, Carston R: 1 article (08/2015)|
06/01/2012 - "Neoplastic cells of the penguin as well as of the pelican were immunoreactive to CD3 antigen, suggesting the lymphomas were of T-cell origin. "
12/01/2008 - "Lymphoblasts in thymic lymphomas stained positively for mouse CD3 antigen, indicating a T-cell lineage. "
10/01/1993 - "Immunohistochemical detection of CD3 antigen (pan T marker) in canine lymphomas."
01/01/1986 - "These results indicated that the rearrangement of immunoglobulin genes could occur in T-cell malignant lymphoma, and that T3 antigen could be expressed prior to the rearrangement of T-cell receptor beta-chain genes under certain circumstances."
06/01/1989 - "We have targeted CD4+ cytotoxic Th (Th/c) lymphocytes to a B cell lymphoma, through the use of a bispecific antibody containing binding sites for both the CD3 complex on the Th/c and the Id on the surface Ig of the B lymphoma (anti-CD3-anti-Id). "
07/01/1988 - "Immunoultrastructural studies using UCHT-1, an antibody to the T-cell receptor-associated CD3 antigen, were therefore performed on four tonsils with reactive follicular hyperplasia and on four follicular center cell lymphomas. "
12/01/1987 - "T-cells in follicular hyperplasia and follicular center-cell lymphomas: an immunoultrastructural study of the T-cell receptor-associated CD3 antigen."
09/01/1995 - "BIS-1 is directed against both the CD3 antigen on T cells and the EGP-2 molecule on carcinoma cells and some normal epithelia. "
06/15/1999 - "We demonstrate that displaying engagement sites for the T-cell antigens CD3 and CD28 on the surface of colon carcinoma cells is a suitable way to activate and retarget T cells in a highly tumor-specific manner. "
11/01/1993 - "BIS-1, the bispecific monoclonal antibody used in this study, combines specificity against a tumour-associated antigen, AMOC-31, present on carcinomas, with a specificity against the CD3 complex on T lymphocytes. "
03/01/1997 - "The cultured cells were negative for various haematopoietic cell markers, including the lymphoid cell antigens CD3, CD20 and CD45, von Willebrandt factor, carcinoembryonic antigen and the carcinoma antigen-125 (CA-125). "
12/01/1994 - "OC/TR is a cell line producing bispecific antibody that reacts with the CD3 antigen on T cells and the folate-binding receptor--frequently found to be overexpressed on ovarian carcinoma cells. "
|4.||Systemic Lupus Erythematosus (Libman-Sacks Disease)
09/01/2008 - "T cells from patients with systemic lupus erythematosus are characterized by decreased expression of CD3zeta-chain and increased expression of FcRgamma-chain, which becomes part of the CD3 complex and contributes to aberrant signaling. "
01/01/1987 - "Modulation of T3 antigen in systemic lupus erythematosus (SLE)."
01/01/1999 - "To study activation of T-lymphocytes by the CD3 (antigen-dependent) and CD2 (non-antigen-dependent) routes in patients with systemic lupus erythematosus (SLE). "
|5.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
|1.||T-Cell Antigen Receptors (T-Cell Receptor)
|4.||Histocompatibility Antigens Class II
|8.||tumor-associated antigen GA733
|10.||HLA-DR Antigens (HLA-DR)
|1.||Drug Therapy (Chemotherapy)